➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Boehringer Ingelheim
Merck
AstraZeneca
Express Scripts

Last Updated: April 17, 2021

DrugPatentWatch Database Preview

Rituximab - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for rituximab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
ITB-Med LLCPhase 2
Paolo GhiaPhase 2
EnteromePhase 1/Phase 2

See all rituximab clinical trials

Recent Litigation for rituximab

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Ravgen, Inc. v. Progenity, Inc.2020-12-20
Ravgen, Inc. v. Myriad Genetics, Inc.2020-12-20
Ravgen, Inc. v. Illumina, Inc.2020-12-02

See all rituximab litigation

PTAB Litigation
PetitionerDate
Celltrion, Inc.2018-05-04
Apotex Inc.2018-02-23
Forty Seven, Inc.2018-01-08

See all rituximab litigation

Pharmacology for rituximab

Patent Text Search: US Patents for rituximab

These patents were identified by searching patent claims

Supplementary Protection Certificates for rituximab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2018 00020 Denmark   Start Trial PRODUCT NAME: AFUCOSYLERET ANTISTOF, DER BINDER TIL ALFA-UNDERENHEDEN AF DEN HUMANE INTERLEUKIN-5-RECEPTOR, SAERLIGT BENRALIZUMAB ELLER EN TERAPEUTISK AEKVIVALENT VARIANT DERAF, SOM ER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/17/1252 20180110
17C/054 Belgium   Start Trial PRODUCT NAME: KEVZARA - SARILUMAB; AUTHORISATION NUMBER AND DATE: EU/1/17/1196 20170627
20/009 Ireland   Start Trial PRODUCT NAME: LAROTRECTINIB AND/OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PARTICULARLY LAROTRECTINIB SULFATE INCLUDING LAROTRECTINIB HYDROGEN SULFATE; REGISTRATION NO/DATE: EU/1/19/1385 20190923
2017000015 Germany   Start Trial PRODUCT NAME: IBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945-C(2015)4704 20150703
2018000056 Germany   Start Trial PRODUCT NAME: EIN AFUCOSYLIERTER ANTIKOERPER, DER AN INTERLEUKIN-5-REZEPTOR ALPHA BINDET, INSBESONDERE BENRALIZUMAB ODER EINE THERAPEUTISCH AEQUIVALENTE VARIANTE DAVON, WIE DURCH DAS GRUNDPATENT GESCHUETZT; REGISTRATION NO/DATE: EU/1/17/1252 20180108
2 50002-2015 Slovakia   Start Trial PRODUCT NAME: POMALIDOMID; REGISTRATION NO/DATE: EU/1/13/850/001 - EU/1/13/850/004 20130808
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
McKinsey
McKesson
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.